ASCO20: immunotherapy combinations for non-small-cell lung cancer, an interview with Grace Dy
We recently interviewed Grace Dy (Professor of Oncology; Roswell Park Comprehensive Cancer Center, NY, USA) about her work presented at the American Society of Clinical Oncology (ASCO) 2020 virtual annual meeting (29 – 31 May 2020). Her background is in early drug development/ Phase I cancer clinical trials of signal transduction inhibitors and immune checkpoint inhibitors in solid tumor malignancies. Currently, Dy is investigating biomarkers to predict the response or resistance to cancer therapy. In this interview, Dy discusses immunotherapy combinations and the search for new cancer therapy targets for non-small-cell lung cancer (NSCLC). How are antibodies currently utilized in...